Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313183 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00313183 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 12 participants.
The verdict
NCT00313183, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these subjects.
Interventions
- DRUG pramlintide acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313183
The ClinicalTrials.gov registry entry for NCT00313183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pramlintide acetate is the first listed.
NCT00313183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313183 about?
NCT00313183 is a clinical study titled "A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus". This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these subjects.
What is the current status of trial NCT00313183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00313183?
The interventions under investigation include: pramlintide acetate (DRUG).
Who is sponsoring clinical trial NCT00313183?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.